arrow
G

Giancarlo Troncone

department of public health
H指数:64
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design and analytical validation of Nexthyro 2.0, a custom next-generation sequencing panel integrating DNA mutation profiling and RNA fusion detection for routine thyroid pathology specimens

Nexthyro 2.0的设计与分析验证,一种定制化下一代测序panel,整合DNA突变分型和RNA融合检测,用于常规甲状腺病理标本

2026-08-310
OAAI
Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers

霍奇金淋巴瘤女性幸存者在年轻成年和成年时期接触非聚乙二醇化脂质体多柔比星后的乳腺癌风险:来自意大利南部癌症中心的首个真实世界病例系列

2026-07-160
OA
Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution

靶向基因面板在晚期实体瘤中的下一代测序应用:一家意大利转诊机构五年的经验

2026-06-030
OAAI
FKBP5 isoforms shape immune pathways related to tumor tolerance

FKBP5异构体塑造与肿瘤耐受相关的免疫通路

2026-03-260
OAAI
Artificial Intelligence in Thyroid Cytopathology: Diagnostic and Technical Insights

甲状腺细胞病理学中的人工智能:诊断与技术见解

Cancers
IF4.4
2026-03-030
OAAI
Type 2 Deiodinase in Cancer-Associated Fibroblasts is Required to Sustain Growth of Poorly and Undifferentiated Thyroid Cancer

癌症相关成纤维细胞中的2型脱碘酶对于维持低分化及未分化甲状腺癌的生长是必需的。

Thyroid
IF6.7
2025-11-270
PRE
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers

Brentuximab Vedotin联合多柔比星、长春碱和达卡巴嗪,用于18-59岁未经治疗晚期经典型霍奇金淋巴瘤患者:来自意大利南部癌症中心的最大真实世界系列研究

2025-11-010
OAAI
Environmental and lifestyle factors and risk of thyroid carcinoma: a cross-sectional study

环境与生活方式因素与甲状腺癌风险:一项横断面研究

2025-10-060
OA
WHOverlap Multicentre Study: Dissecting the Insufficient/Inadequate/Non-Diagnostic Category and Its Overlap with the Benign Category in the WHO Reporting System for Lung Cytopathology

WHOverlap多中心研究:解析WHO肺癌细胞病理学报告系统中的不足/不充分/非诊断类别及其与良性类别的重叠情况

2025-10-010
PRE
Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study

一种泛癌种NGS检测试剂盒的分析验证:用于院内液体活检检测的国际多中心研究

2025-09-250
PREAI
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer

液体活检在精准肿瘤学中的最新进展:新兴生物标志物及其在肺癌中的临床应用

2025-08-050
PRE
Smaller, cheaper, faster: where next for liquid biopsies?

更小、更便宜、更快:液体活检的未来走向何方?

2025-07-140
PRE
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors

AP1介导的EGFR表达重编程触发了RET易位肿瘤对BLU-667和LOXO-292的耐药性

2025-05-220
OA
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2-breast cancer after progression on CDK4/6 inhibitor therapy

在HR+/HER2-乳腺癌患者对CDK4/6抑制剂治疗进展后,对来自转移灶的FFPE样本进行ESR1基因检测

2025-05-140
OA